The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.
Tan, Jun; Luo, Deyan; and Shytle, Roland Douglas, "Luteolin and diosmin/diosmetin as novel STAT3 inhibitors for treating autism" (2014). USF Patents. 137.
University of South Florida